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The MEP (Methyl Erythritol Phosphate) isoprenoids biosynthesis pathway is an attractive
drug target to combat malaria, due to its uniqueness and indispensability for the
parasite. It is functional in the apicoplast of Plasmodium and its products get transported
to the cytoplasm, where they participate in glycoprotein synthesis, electron transport
chain, tRNA modification and several other biological processes. Several compounds
have been tested against the enzymes involved in this pathway and amongst them
Fosmidomycin, targeted against IspC (DXP reductoisomerase) enzyme andMMV008138
targeted against IspD enzyme have shown good anti-malarial activity in parasite cultures.
Fosmidomycin is now-a-days prescribed clinically, however, less absorption, shorter
half-life, and toxicity at higher doses, limits its use as an anti-malarial. The potential of
other enzymes of the pathway as candidate drug targets has also been determined.
This review details the various drug molecules tested against these targets with special
emphasis to Plasmodium. We corroborate that MEP pathway functional within the
apicoplast of Plasmodium is a major drug target, especially during erythrocytic stages.
However, the major bottlenecks, bioavailability and toxicity of the new molecules needs
to be addressed, before considering any new molecule as a potent antimalarial.
Keywords: Plasmodium, apicoplast, isoprenoids, MEP pathway, anti-malarial
INTRODUCTION
Isoprenoids are structurally and functionally the most diverse group of natural metabolites found
in all three domains i.e., eubacteria, archaebacteria and eukarya. Depending on the number of
precursor units [Isopentenyl Pyrophosphate (IPP) and Dimethylallyl Pyrophosphate (DMAPP)],
they vary in structure and functions. Isoprenoids are known to play a key role in all aspects of
life; e.g., in regulation of gene expression (prenylation of proteins), as membrane constituents
(prenyl lipids in archaebacteria and sterol in eubacteria and eukaryotes), as vitamins, plant
hormones (gibberellins, brassinosteroids, abscisic acid), photosynthetic pigments (carotenoids,
side chain of chlorophyll), quinones in electron transport chain, and plant defense compounds
(monoterpenes, sesquiterpenes, diterpenes) (Sacchettini and Poulter, 1997; Bach et al., 1999;
Hunter, 2007). Two distinct pathways synthesize IPP and DMAPP, (a) the Mevalonate dependent
pathway (MVA) functional in archaea and most eukaryotes (including all mammals and higher
plants), and (b) the Methyl Erythritol Phosphate/1-deoxy-D-xylulose-5-phosphate (MEP/DOXP)
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pathway functional in bacteria, plant plastids, members of
chlorophyta and pathogenic microorganisms (Banerjee and
Sharkey, 2014). These pathways are significantly different from
each other (Figure S1) in terms of preliminary substrates,
mevalonate as an intermediate in MVA pathway only, and higher
yield of IPP and DMAPP in MEP pathway.
Isoprenoids Biosynthesis in Plasmodium
Plasmodium belongs to the phylum Apicomplexa, known to
harbor a non-photosynthetic plastid like organelle of prokaryotic
origin known as apicoplast (McFadden et al., 1996; Foth and
McFadden, 2003). This organelle is indispensable for the survival
of the parasite and is the functional site for four major metabolic
pathways. The MEP/DOXP pathway is one of these pathways
which is the only source for isoprenoids in the parasite and is
absent in the human host. The first evidence for the presence
of the MEP pathway in Plasmodium was given by Jomaa et al.
(1999) who identified the presence of DOXP reductoisomerase
(IspC) gene in preliminary staged Plasmodium falciparum whole
genome database. Following this, few other enzymes of this
pathway, IspD (Rohdich et al., 1999), IspF (Rohdich et al.,
2001), IspG (Altincicek et al., 2001a), and IspH (Altincicek
et al., 2001b) were characterized mainly from prokaryotes and
were shown to be present in P. falciparum as well. Studies
have detailed the import of initial substrates of the pathway,
DHAP (Dihydroxy acetone phosphate) and PEP (Phosphoenol
pyruvate) inside the Plasmodium apicoplast with the help of
transporter molecules TPT (triose phosphate transporter) and
PPT (phosphoenol pyruvate transporter) respectively, localized
in the apicoplast membrane (Mullin et al., 2006) suggesting
apicoplast as its functional site.
In Plasmodium, the MEP pathway is reported to be
indispensable for both hepatic (Sparr et al., 2013) and
erythrocytic stages (Cassera et al., 2004) of the parasite asexual
life cycle. Recent reports have suggested that the “apicoplast
less” Plasmodium parasite can divide indefinitely in culture if
supplemented exogenously with IPP. This proves that during
the erythrocytic stages, the only essential function of apicoplast
is the synthesis of isoprene unit precursors, IPP and DMAPP
(Yeh and DeRisi, 2011). Recent reports have also proven that
the products of MEP pathway are required in the early stages of
parasite gamete development (Wiley et al., 2015). All these studies
suggest the importance of this pathway at different phases of the
parasite’s life cycle.
MEP Pathway Enzymes
The MEP pathway consists of seven enzymes, encoded by
the parasite nuclear genome and targeted to apicoplast with
the help of N-terminal bipartite leader sequence (van Dooren
et al., 2002). While all these enzymes are well characterized in
prokaryotes like Escherichia coli, only a few have been detailed
from pathogenic organisms including Plasmodium. Here, we
have detailed a comparative analysis of each enzyme of the
pathway from different organisms and discussed the various
natural and chemically derived molecules used as their inhibitors
in recent years with special emphasis to Plasmodium (Table 1).
DXS (DXP Synthase)
The initial substrates pyruvate and Glyceraldehyde-3-Phosphate
are acted upon by a thiamine pyrophosphate dependent
enzyme DXS (EC 4.1.3.37) to generate 1-deoxy-D-xylose-5-
phosphate (DOXP/DXP) (Sprenger et al., 1997). This first
step is believed to be rate limiting in some organisms and
represents a branch point for Vitamin B and isoprenoids
synthesis in bacteria (Hahn et al., 2001). The X-ray crystal
structure of DXS enzyme has been elucidated from E. coli
(PDB Id: 2O1S) and Deinococcus radiodurans (PDB Id: 2O1X).
This enzyme consists of three functional domains: Thiamine
Pyrophosphate (TPP/ThDP) binding domain, Pyrimidine (PYR)
binding domain and transketolase C domain. In E. coli, the
interaction of ThDP and Mg2+ has been observed with amino
acid residues present in the TPP DXS domain (Xiang et al.,
2007). However, in Plasmodium, the characterization of DXS
from both P. falciparum and P. vivax suggests its existence as
a homodimer (Handa et al., 2013) which contains one-bound
Mg (II) per enzyme molecule, having both a catalytic and
structural role in the enzyme. All ThDP dependent enzymes
catalyze two successive half reactions. The first step involves
the attack of an activated ThDP ylide on the first substrate
GA3P. The next step can occur via three distinct mechanisms: (i)
the most common classical ping-pong mechanism; (ii) through
an ordered sequential kinetic mechanism or (iii) through an
alternate random sequential mechanism (Brammer et al., 2011).
Enzyme kinetics of DXS in Plasmodium points toward a random
sequential kinetic mechanism, an unusual finding for ThDP-
dependent enzymes similar to Rhodobacter capsulatus (Battistini
et al., 2016).
In Mycobacterium tuberculosis, transketolase inhibitors like
derivatives of Pyrimidinone (IC50 = 10.6 µM) have been shown
to inhibit DXS enzyme (Mao et al., 2008). Later, a herbicide
Ketoclomazone was shown to inhibit the DXS enzyme in both
E. coli and Haemophilus influenzae by binding to a site, which
differs from both the pyruvate and GA3P binding sites, thus
suggesting non-competitive inhibition (Matsue et al., 2010).
However, yet, the binding site of the drug is not elucidated.
In another study, Smith et al. (2014) has demonstrated the
selective inhibition of ThDP dependent enzymes in E. coli,
Yersinia pestis, and M. tuberculosis by unnatural by-substrate
analog butylacetylphosphonate (BAP) and its synergistic action
with established anti-microbial agents like Fosmidomycin (Fos).
However, BAP exhibits weak anti-microbial activity, possibly
due to poor cellular uptake. Recently, analogs of pyruvate, β-
Fluoropyruvate (F-Pyr) and methylacetylphosphonate (MAP)
were demonstrated as competitive inhibitors of the DXS enzyme
in both P. falciparum and P. vivax (Handa et al., 2013; Battistini
et al., 2016).
IspC (DXP Reductoisomerase/DXR)
IspC (EC 1.1.1.267) is the first enzyme committed to the
isoprenoids biosynthesis in the MEP pathway. In a rate limiting
step, it is responsible for the conversion of DOXP to 2-C-
methyl-D-erythritol-4-phosphate (MEP) by using the NADPH
pro-S hydride (Brammer et al., 2011). Its structure has been well
defined in E. coli (PDB Id: 1Q0L; Mac Sweeney et al., 2005),
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TABLE 1 | Inhibitors reported for different enzyme involved in the MEP pathway with their chemical properties.
Gene/
Protein
Enzyme Inhibitor molecules Inhibition
mechanism
Organism with
IC50 value
References
DXS 1-deoxy-D-xylose-
5-phosphate (DXP)
Synthase
*6-benzyl-3-(4-
chlorophenyl)-5-methyl-2-
(trifluoromethyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one
Competitive
inhibition
M. tuberculosis
(IC5010.6 µM)
Mao et al., 2008
Ketoclomazone PubChem
CID: 12811046
Non
competitive
inhibition
E. coli (IC50800
µg/mL) and H.
influenzae
(IC5012.5 µg/mL)
Matsue et al.,
2010
β-fluoropyruvate
PubChem CID: 67946
Competitive
inhibition
P. vivax (IC5035 ±
1.7 µM) P.
falciparum (IC5043
± 3.8 µM)
Battistini et al.,
2016
Methylacetylphosphonate
PubChem CID: 23674726
Competitive
inhibition
P. vivax (IC5080
µM) P. falciparum
(IC5046 ± 3.8 µM)
IspC DXP
reductoisomerase
Fosmidomycin PubChem
CID: 572
Competitive
inhibition
P. falciparum
(IC50350 ±
170 nM)
Jomaa et al.,
1999; Lell et al.,
2003; Umeda
et al., 2011
FR900098 PubChem CID:
162204
Competitive
inhibition
P. falciparum
(IC50170 ±
100 nM)
Jomaa et al.,
1999
*[1-(3,4-Difluorophenyl)-4-
(hydroxylamino)-4-
oxobutyl] phosphonic acid
(Fosmidomycin reverse
derivative)
Competitive
inhibition
P. falciparum
(IC503 nM)
Behrendt et al.,
2011
*((3,4-Difluorophenyl)(2-
(hydroxy(methyl)amino)-2-
oxoethoxy)methyl)
phosphonic acid
Competitive
inhibition
P. falciparum
(IC5012 nM)
Brücher et al.,
2012
(Continued)
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TABLE 1 | Continued
Gene/
Protein
Enzyme Inhibitor molecules Inhibition
mechanism
Organism with
IC50 value
References
*4-
[Hydroxy(methyl)amino]-1-
(4-methoxyphenyl)-4-
oxobutylphosphonic acid
(Fosmidomycin reverse
analog
Competitive
inhibition
P. falciparum
(IC5020 nM)
Konzuch et al.,
2014
IspD 2-C-methyl-D-
erythritol
4-phosphate
cytidylyltransferase
*L-erythritol-4-phosphate Competitive
inhibition
B. abortus
(IC501.36mM)
Lillo et al., 2003
7-hydroxy-[1,2,4] triazolo
[1,5-a] pyrimidine
PubChem CID: 75629
(2503-56-2)
Allosteric
inhibition
A. thaliana
(IC50140 ± 10 nM)
Witschel et al.,
2011
*6-Amino-7-(1H-
benzo[d]imidazol-2-yl)-5-
[5-(diethylamino)-1-
methylbut-1-yl)-5H-pyrrolo
[3,2-b]
pyrazine-2,3-dicarbonitrile
Non
competitive
inhibition
P. falciparum
(EC50 50 nM)
Reker et al., 2014
Pyrroloquinoxaline Non
competitive
inhibition
A. thaliana (IC50
1.6 µM)
Reker et al., 2014
MMV008138 PubChem
CID: 2829106
Competitive
inhibition
P. falciparum
(IC5047 nM) and P.
vivax (IC50310 nM)
Imlay et al., 2015
(Continued)
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TABLE 1 | Continued
Gene/
Protein
Enzyme Inhibitor molecules Inhibition
mechanism
Organism with
IC50 value
References
*Ethyl {3-[4-amino-5-{3-
[(cyclopropylsulfonyl)
amino] prop-1-yn-1-yl}-2-
oxopyrimidin-1(2H)-yl]
oxetan-3-yl} acetate
Competitive
inhibition
A. aeolicus
(IC50590 ± 10 nM)
Hirsch et al.,
2008
IspE 4-(cytidine-5-
diphospho)-2-C-
methyl-D-erythritol
kinase
6-(benzylthio)-2-(2-
hydroxyphenyl)-4-oxo-
3,4-dihydro-2H-1,3-
thiazine-5-carbonitrile
PubChem CID: 3768522
Competitive
inhibition
E. coli (IC505.5
µM)
Tang et al., 2011
*Diammonium 5′-O-{[({[2-
({[5-(Dimethylamino)
naphthalene-1-
yl]sulfonyl}amino) ethyl]
oxy}phosphinato)oxy]
phosphinato} cytidine
Competitive
inhibition
E. coli (IC503.0
µM)
Crane et al., 2006
IspF 2C-Methyl-D-
erythritol-2,
4-cyclodiphosphate
synthase
Thiazolopyrimidine
PubChem CID: 330031
Competitive
inhibition
P. falciparum
(IC509.6 µM) and
M. tuberculosis
(IC506.1 µM)
Geist et al., 2010
Aryl bis sulphonamide
PubChem CID: 5333
Competitive
inhibition
P. falciparum
(IC501.4 µM) and
A. thaliana
(IC50240 nM)
Thelemann et al.,
2015
Propargyl diphosphate
PubChem CID: 46236597
Competitive
inhibition
E. coli
(IC50750 nM)
Wang et al., 2010
IspG 4-Hydroxy-3-
methyl-2-(E)-
butenyl-4-
diphosphate
synthase
Prop-2-yn-1-yl
trihydrogen diphosphate
PubChem CID: 448670
Competitive
inhibition
T. thermophilus
(IC50770 nM)
Quitterer et al.,
2015
But-3-yn-1-yl trihydrogen
diphosphate PubChem
CID: 46236598
Competitive
inhibition
T. thermophilus
(IC50580 nM)
Wang et al., 2010
(Continued)
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TABLE 1 | Continued
Gene/
Protein
Enzyme Inhibitor molecules Inhibition
mechanism
Organism with
IC50 value
References
But-3-yn-1-yl trihydrogen
diphosphate PubChem
CID: 46236598
A. aeolicus
(IC50450 nM)
IspH 4-Hydroxy-3-
methyl-2-(E)-
butenyl-4-
diphosphate
reductase
Pyridine phosphate
PubChem CID: 10866885
Competitive
inhibition
A. aeolicus
(IC5035 µM)
Wang et al., 2011
*(E)-4-mercapto-3-methyl
but-2 enyl diphosphate
(Alkyne diphosphate
derivative)
Competitive
inhibition
E. coli
(IC50210 nM)
Janthawornpong
et al., 2013
*PubChem Id not available.
P. falciparum (PDB Id: 3AU9; Umeda et al., 2011, 2015) and
various other pathogens, including M. tuberculosis (PDB Id:
2Y1C; Andaloussi et al., 2011) and Zymomonas mobilis (PDB Id:
1ROK; Ricagno et al., 2004; Henriksson et al., 2006). It is a class B
dehydrogenase enzyme that exists as a homodimer where each
subunit is composed of three domains; an N-terminal domain
for cofactor binding (DXP_reductoisom), central domain having
active site residues (DXP_redisom_C) and a C-terminal helical
domain (DXPR_C). The N-terminal domain is a member of
dinucleotide binding fold and serves for binding of NADPH.
The central catalytic domain harbors the binding sites for
divalent cations (like Mn2+ or Mg2+), phosphate of the substrate
and the catalytic loop. The C-terminal domain is connected
to the catalytic domain by a linker region that spans entire
monomer and appears to have a structural role in supporting
the catalytic domain. Normally, the active site has two different
conformations, open and closed. The open conformation allows
the substrate, DXP, to enter and bind to the active site while
in the closed conformation, a flap covers the active site and
catalytic function is activated (Mac Sweeney et al., 2005). In P.
falciparum IspC, NADPH molecule bind to the cavity composed
of conserved residues D231, E233, S269, S270, W296, M298,
S306, N311, K312, and E315 present toward the C-terminal of
the enzyme. These residues are conserved in all human malaria
parasites (Kunfermann et al., 2013).
In E. coli and P. falciparum, Fos has been characterized as
an inhibitor (IC50 = 0.032 µM) of IspC enzyme. It behaves
as a substrate analog of DOXP and competes for its binding
site on IspC (Jomaa et al., 1999; Steinbacher et al., 2003). In
P. falciparum, Fos interacts with K205, D231, S232, S269, S270,
N311, K312, and E315 residues of the catalytic domain (Figure 1;
Umeda et al., 2011). The effect of Fos has been reported to
be varied amongst different stages of Plasmodium development
as well as amongst different apicomplexans. It was found that
Fos is only effective on the erythrocytic stages of Plasmodium
due to the formation of new permeability pathways (minute
anionic selective channels formed due to entry of parasite
in erythrocytes), but has no or minimal effect on the liver
stages of P. berghei. In addition, Fos is not effective on many
apicomplexans including Toxoplasma, Eimeria even at higher
concentrations, probably due to its impermeability to the parasite
plasma membrane (Baumeister et al., 2011; Nair et al., 2011).
Fos is one of those few drugs which was able to qualify
the Phase–II clinical trials (in combination with Clindamycin),
however, its treatment faces several drawbacks, including low
bioavailability, rapid clearance from the parasite, less absorption
(16.6 µg/mL after an oral dose of 40 mg/kg) and shorter
half–life (1.14 h) leading to incidences of recurrence. Due to
its toxicity at higher doses, this drug alone could not act as
potential antimalarial (Murakawa et al., 1982; Kuemmerle et al.,
1987; Lell et al., 2003). To overcome the bottlenecks in the use
of Fos as an anti-malarial, different groups have synthesized
analogs of Fos. Jansson et al. (2013) reported various analogs
of Fos but only one among these, a disubstituted Fos (1-(3,4-
Dichlorophenyl)-3-(N-hydroxyphenylamido) propylphosphonic
acid) was shown to have equivalent activity (IC50 = 0.04 µM)
as Fos. Recently, a Fos derivative (phosphonohydroxamates) was
observed to inhibit parasite growth in the in-vitro culture of P.
falciparum Dd2 strain, resistant to chloroquine and mefloquine
(Faísca Phillips et al., 2015). In search of better derivatives of
Fos, reverse analogs of Fos were also synthesized. Behrendt et al.
(2011) synthesized the reverse hydroxamate based inhibitors
amongst which [1-(3,4-Difluorophenyl)-4-(hydroxylamino)-4-
oxobutyl] phosphonic acid is considered most effective with an
IC50 of 3 nM. Later Brücher et al. (2012) synthesized α-Aryl-
substituted β-oxa isosteres of Fos with a reverse orientation of the
hydroxamic acid group and tested them against recombinant P.
falciparum IspC and chloroquine-sensitive and resistant strains
of P. falciparum. They found an inhibitory activity of these
derivatives against P. falciparum IspC, with the most active
derivative ((3,4-Difluorophenyl) (2-(hydroxy(methyl)amino)-2-
oxoethoxy) methyl) phosphonic acid showing an IC50 value of
12 nM and potent in-vitro anti-plasmodial activity. Following
similar approach for synthesis of reverse analogs, Konzuch et al.
(2014) showed a new compound 4-[Hydroxy(methyl)amino]-
1-(4-methoxyphenyl)-4-oxobutylphosphonic acid, to exhibits
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FIGURE 1 | X-ray crystal structure (PDB Id: 3AU9; Umeda et al., 2011) of P. falciparum IspC enzyme interacting with Fosmidomycin (represented as
stick). The drug interacts with K205, D231, S232, S269, S270, N311, K312, and E315 residues of enzyme. CPK color scheme followed and distance represented
in Å.
more than one order of magnitude of activity in comparison
to Fos.
Another approach has been tried by Haymond et al. (2014),
where several compounds from resolved crystal structures of
M. tuberculosis MEP synthase in complex with Fos were
designed, containing an amide-linked or O-linked functional
group. The strategy was to target two major binding sites in
MEP synthase; the Fos/DXP site and the NADPH site, bridging
these adjacent sites to yield a highly specific inhibitor ligand.
Amongst the compounds tested, the most effective inhibitor
(diethyl 3-(benzyloxyamino) propylphosphonate) binds to both
the NADPH and DXP sites, acting as a potent tight binding
inhibitor of the enzyme in both M. tuberculosis and Y. pestis.
However, a growth inhibition secondary screen revealed that the
whole-cell inhibitory activity of this compound is relatively poor,
indicating the need for additional structure-activity relationship
studies to elucidate the underlying etiology.
Apart from the synthesis of Fos derivatives, various other
trials are underway to increase the efficacy of Fos. Nair et al.
(2011) had shown the increase in permeability and uptake of
Fos in T. gondii in presence of recombinant GA3P transporter
(GlpT) protein of E. coli. Similarly, Sparr et al. (2013) has recently
reported a mechanism of tagging Fos with cell penetrating
peptides consisting of octa-arginine which could ultimately block
the hepatic stages of the parasite.
IspD [2-C-Methyl-D-Erythritol 4-Phosphate
Cytidylyltransferase (YgbP)]
IspD (EC 2.7.7.60) enzyme, catalyzes the cytidylation process and
participates in the third step of the pathway where its activity is
highly dependent upon divalent cations Mg2+ or Mn2+ (Richard
et al., 2001). Nucleotide derivatives, i.e., Cytosine-5′-triphosphate
(CTP) and phosphate groups i.e., 2-C-methyl-D-erythritol-4-
phosphate (MEP) are introduced directly as substrates in the
IspD catalyzed reaction and produces 4-diphosphocytidyl-2C-
methyl-D-erythritol (CDP-ME) with pyrophosphate as a bi-
product. The catalytic mechanism of IspD enzyme is unique and
comes under the category of associative mechanism. According
to this process, when there is a nucleophile attack on the α-
phosphate of CTP by the 4-phosphate of MEP, a negatively
charged penta-coordinate transition state is formed. The collapse
of this charged transition state finally leads to pyrophosphate
release and CDP-ME formation. Two lysine residues (Lys27
and Lys213 in E. coli IspD) are critical to stabilize this
pentavalent transition state (Richard et al., 2004). Amino acid
alignments show that the basic residues in the IspD active site,
in particular the E. coli IspD Lys27/Lys213 are also conserved
in P. falciparum (Hunter, 2011). The X-ray crystal structure
of IspD protein is known from several organisms, such as M.
tuberculosis (PDB Id: 2WXN; Björkelid et al., 2011), Thermotoga
maritima (PDB Id: 1VPA; unpublished), Neisseria gonorrhoeae
(PDB Id: 1VGZ; Badger et al., 2005), Thermus thermophilus
(PDB Id: 2PX7; unpublished), Listeria monocytogenes (PDB Id:
3F1C; unpublished) and Arabidopsis thaliana (PDB Id: 1W77;
Gabrielsen et al., 2006). The presence of a conserved CDP-
ME synthase domain (GT-A superfamily) is important for the
functionality of IspD enzyme and follows a Rossmann fold
arrangement which only allows the sequestration of pyrimidine
nucleotide i.e., CTP. The presence of two signature motifs GXG
and [IVT] -[LIVMC] -[IVT] -[HS] -D-[SGAV] -[AV] -R is
another important feature of IspD enzymewhere the Glycine rich
GXG motif at N- terminal provides a proper orientation for the
binding of substrate near to the other conserved signature motif
of the enzyme (Shi et al., 2007).
The first inhibitor of IspD enzyme was reported from Brucella
abortus, where a compound named L-erythritol-4-phosphate
(E4P) showed an IC50 of 1.36 mM (Lillo et al., 2003). Later,
Witschel et al. (2011) showed the inhibition of IspD in A.
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thaliana by a synthetic compound 7-hydroxy [1,2,4] triazolo [1,5-
a] pyrimidine (Azolopyrimidine). Crystallization studies of this
compound with IspD showed interactions at R157, Q238, D261,
S264, I265, and V266 residues (Figure 2) suggesting an allosteric
inhibition. Further, direct enzyme based assays by Reker et al.
(2014) suggested Pyrrolopyrazines derivatives as potent inhibitor
of A. thaliana IspD. They have also shown the potential of these
pyrrolopyrazines for inhibiting the growth of malaria parasite
in cell based assays, where, 6-Amino-7-(1H-benzo[d]imidazol-
2-yl)-5-[5-(diethylamino)-1-methylbut-1-yl)-5H-pyrrolo [3,2-b]
pyrazine-2,3-dicarbonitrile was shown to be effective at nano
molar concentration. However, the authors have also suggested
an additional mechanism of action for the compound in
Plasmodium. In another study, highly halogenated marine
alkaloid of class pseudilins isolated from the marine bacterium
Pseudomonas bromoutilis exhibited both herbicidal and anti-
malarial activity (EC50 of 1–12µM in cell based assays). However,
cytotoxicity of these pseudilins in mammalian cell also suggests
additional molecular targets apart from IspD (Kunfermann et al.,
2014). Recently, another inhibitorMMV008138 (shortlisted from
Malaria Box) was found effective against Pf IspD enzyme showing
competitive inhibition with CTP substrate (Wu et al., 2015; Yao
et al., 2015), whereas, in P. vivax, it is effective only at a lower
concentration of CTP substrate (Imlay et al., 2015). In addition,
MMV008138 does not exhibit activity against liver stages of
P. yoelli nor does it have activity against sexual stages of P.
falciparum (Bowman et al., 2014). Thus, further investigation is
required for using MMV008138 as a common inhibitor for the
IspD enzyme of both P. falciparum and P. vivax.
IspE [4-(Cytidine-5-Diphospho)-2-C-Methyl-D-
Erythritol Kinase (CMK)]
The fourth step of the pathway is catalyzed by IspE (EC 2.7.1.148)
enzyme, an ATP and Mg2+ dependent enzyme belonging to
the ATP–dependent GHMP kinase super-family (Andreassi and
Leyh, 2004). It catalyzes the conversion of CDP-ME to 4-
diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate (CDP-
ME2P) in an ATP-dependent manner. The X-Ray crystal
structure of IspE has been elucidated from E. coli, T. thermophilus
HB8 (PDB Ids: 2WW4 and 1UEK; Wada et al., 2003), Aquifex
aeolicus (PDB Id: 2VF3; Sgraja et al., 2008) and M. tuberculosis
(PDB Id: 3PYD; Shan et al., 2011). The IspE enzyme exists
as a monomer and displays the characteristic two-domain fold
of the GHMP kinase superfamily. The active site of IspE is
enclosed in a deep cleft between these two domains (Rohdich
et al., 2000) where three known conserved motifs are present.
Motif A (Lys13 to Leu18) forms the substrate binding site,
Motif B (Gly102 to Ser107) forms a glycine-rich phosphate
binding loop that interacts with the ATP and Motif C (Val254
to Gly258) helps to stabilize the conformation of motifs A and
B rather than interacting with ligands directly (Sgraja et al.,
2008; Eoh et al., 2009; Shan et al., 2011). In addition, a small,
hydrophobic pocket lies adjacent to the CDP-binding site lined
by amino acids Leu14, Ile27, Tyr175, and Leu208 (Hirsch et al.,
2007).
Hirsch et al. (2008) used the structure-based design approach
and developed various inhibitors to target the substrate instead
of enzyme. On screening of these compounds, Ethyl {3-
[4-amino-5-{3-[(cyclopropylsulfonyl) amino] prop-1-yn-1-yl}-
2-oxopyrimidin-1(2H) -yl] oxetan-3-yl} acetate was found to
be the most promising candidate with an IC50 of 590 ± 10
nM. Further, co-crystallization studies of IspE enzyme along
with this inhibitor in E. coli and A. aeolicus confirmed that
the inhibitor fits properly in the cytidine-binding pocket of the
enzyme, where the cyclopropyl substituent of the sulfone moiety
occupies the small cavity not used by the substrate (Figure 3).
The highly hydrophobic Phe185 in E. coli IspE is replaced with
a more hydrophilic tyrosine (Tyr) residue in M. tuberculosis, P.
falciparum and A. aeolicus, affecting the binding characteristics
of this pocket, by strongly reducing its hydrophobic character.
Thus, the cyclopropyl ring may not locate to this sub-pocket
FIGURE 2 | X-ray crystal strucuture (PDB Id: 2YC3; Witschel et al., 2011) of A. thaliana IspD interacting with Azolopyrimidines (represented as stick).
The inhibitory molecule 7-hydroxy-[1,2,4] triazolo [1,5-a] pyrimidine interact with R157, Q238, D261, S264, I265, and V266 residues of enzyme. CPK color scheme
followed and distance represented in Å.
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FIGURE 3 | X-ray crystal strucuture (PDB Id: 2VF3; Hirsch et al., 2008) of A. aeolicus IspE interacting with ethyl {3-[4-amino-5-{3-[(cyclopropylsulfonyl)
amino] prop-1-yn-1-yl}-2-oxopyrimidin-1(2H)-yl] oxetan-3-yl} acetate (represented as stick). The inhibitory molecule interacts with N11, H25, Y31, D130,
K145, and T171 residues of enzyme. CPK color scheme followed and distance represented in Å.
and indeed, the cyclopropyl ring prevents any solvation of the
phenolic hydroxyl group of Tyr175. This explains the reduced
inhibitory activity of the above compound againstA. aeolicus and
P. falciparum IspE (Hirsch et al., 2007, 2008).
In another study, from a list of existing small molecule
inhibitors of GHMP kinases, Tang et al. (2011) identified
and confirmed two novel scaffold classes of CDP-ME kinase
inhibitors in E. coli; 6-(benzylthio)-2-(2-hydroxyphenyl)-4-oxo-
3,4-dihydro-2H-1,3-thiazine-5-carbonitrile and (Z)-3-methyl-4-
((5-phenylfuran-2-yl) methylene) isoxazol-5(4H)-one. Selection
of these compounds was based on the predicted binding mode
where 6-benzylthio and 5-phenylfuran ring moieties present
in these compounds show a strong pi-pi interaction with
cytidine binding pocket of CDP-ME created by three critical
residues, viz. Tyr25, His26, and Phe185. In addition, binding
of first compound show that its central core dihydro-2H-1,3-
thiazine-5-carbonitrile –C=O mimics the α-, β-phosphates of
substrate CDP-ME and participates in H-bonding interaction
with Asp141 –NH...O-, whereas the 2-hydroxy-aryl ring position
toward the binding site of the D-erythritol moiety of CDP-
ME. IC50 values of these compounds were 18 and 5.5 µM,
respectively. Substructure search and docking experiments based
on these two scaffolds further identified 23 analogs for structure-
activity relationship (SAR) studies. Three new compounds
from the isoxazol-5(4H)-one series have shown inhibitory
activities against E. coli and Y. pestis CDP-ME kinases with
the IC50 values ranging from 7 to 13 µM (Tang et al.,
2011).
Another compound which has shown inhibitory activity
against Pf IspE is 1,3-diiminoisoindoline carbohydrazide with
an IC50 value <100 nM in cell based assay. Synthesis of a
variety of derivatives allowed an improvement of the initial
antimalarial activity down to IC50 = 18 nM for the most potent
compound (Mombelli et al., 2012). However, till date, none of
the tested derivatives have shown any inhibitory activity against
P. falciparum IspE in-vitro below 100 µM (Masini and Hirsch,
2014), which demands further investigation into this enzyme.
IspF [2C-Methyl-D-Erythritol-2, 4-Cyclodiphosphate
Synthase (ygbB)]
IspF (EC 4.6.1.12) catalyzes the conversion of CDP-ME-2P into
2-C-methyl-D-erythritol-2,4-cyclodiphosphate (MECP), and like
IspD, is dependent on divalent cations Zn2+ or Mn2+ for its
activity. X-ray crystal structures of IspF from E. coli (PDB Id:
2GZL; Crane et al., 2006); (PDB Id: 1KNJ; Richard et al., 2002);
(PDB Id: 1U3L; Steinbacher et al., 2002), A. thaliana (PDB
Id: 2PMP; Calisto et al., 2007), H. influenzae (PDB Id: 1VH8;
Lehmann et al., 2002), M. smegmatis (PDB Id: 2UZH; Buetow
et al., 2007), P. vivax (PDB Id: 3BN6) and P. falciparum (PDB
Id: 4C81; O’Rourke et al., 2014) have been determined, showing
formation of a homo-trimeric quaternary structure. The active
sites are located at the interface of two monomer units where the
pocket involved in binding the phosphate moiety of the substrate
is capped with a flexible loop that becomes completely ordered
when the reaction product is bound. In E. coli, the downstream
products of Isoprenoids pathway like geranyl- or farnesyl-
pyrophosphate have been observed to bind IspF trimers at the
central hydrophobic cavity, which suggests a possible feedback
inhibition of the enzyme (Kemp et al., 2005). However, in
Plasmodium, reports of geranyl pyrophosphate interacting with
IPP in the cytoplasm (Jordão et al., 2013) indicates that though
IspF is present as homo-trimer in P. falciparum apicoplast, it
may not be affected by any feedback mechanism of geranyl
pyrophosphate localized in cytoplasm.
Despite the fact that the active site of IspF is considered
the most druggable, based on the presence of high apolar
amino acid residues, very few inhibitors have been reported.
Crane et al. (2006) tested various anthranilate compounds
with cytidine moiety, amongst which fluorescent diammonium
5′-O-{[({[2-({[5-(Dimethylamino) naphthalene-1- yl] sulfonyl}
amino) ethyl] oxy} phosphinato) oxy] phosphinato} cytidine was
found to be effective against E. coli IspF. In in-vitro studies,
this inhibitor was reported to interact with S35, D56 and E77
residues of E. coli IspF enzyme (Figure 4). The most successful
inhibitors identified till date for IspF are non-cytidine-like
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FIGURE 4 | X-ray crystal strucuture (PDB Id: 2GZL; Crane et al., 2006) of E. coli IspF interacting with diammonium 5′-O-{[({[2-({[5-(Dimethylamino)
naphthalene-1- yl]sulfonyl}amino) ethyl] oxy}phosphinato)oxy] phosphinato} cytidine (represented as stick). The fluorescent inhibitory molecule interacts
with S35, D56, and E77 residues of enzyme. CPK color scheme followed and distance represented in Å.
thiazolopyrimidine derivatives, with high activity against both P.
falciparum (IC50 = 9.6 µM) andM. tuberculosis IspF (IC50 = 6.1
µM) (Geist et al., 2010), and the aryl bis-sulphonamide inhibitors
showing inhibition of P. falciparum IspF and A. thaliana IspF
with IC50 values as low as 1.4 µM and 240 nM, respectively
(Thelemann et al., 2015). However, their binding mode and
optimization is yet to be reported.
IspG [4-Hydroxy-3-Methyl-2-(E)-Butenyl-4-
Diphosphate Synthase (gcpE)] and
IspH [4-Hydroxy-3-Methyl-2-(E)-Butenyl-4-
Diphosphate Reductase (lytB)]
IspG and IspH enzymes participate in the last two steps of the
pathway, respectively. Initially, IspG catalyzes the reduction of
MECP through a multistep reaction and converts it into 4-
hydroxy-3-methyl-2-(E)-butenyl-4-diphosphate (HMBDP) and
then IspH converts it to IPP and DMAPP (Rohdich et al., 2002).
The X-ray crystal structure of IspG has been derived from A.
aeolicus (PDB Id: 3NOY; Lee et al., 2010) and T. thermophilus
(PDB Id: 2YOF; Rekittke et al., 2011). The IspG enzyme consists
of two conserved domains: an N-terminal TIM barrel domain
for the binding of MECP substrate and a C-terminal domain
for binding of Fe-S clusters. In P. falciparum, the electrons
required for the binding of MECP substrate to the IspG enzyme
are provided by ferredoxin/ferredoxin NADP+ reductase system
through [4Fe-4S] clusters (Röhrich et al., 2005). This binding of
the MECP substrate is responsible for the formation of a double
bond that converts cyclic form of theMECPmolecule to aliphatic
HMBDP.
The HMBDP formed by IspG is then converted to the IPP
and DMAPP by IspH enzyme and this conversion consists of
three steps: (i) removal of a hydroxyl group, (ii) transfer of two
electrons from the [4Fe-4S] cluster, and (iii) the protonation
of an intermediate allylic anion (Laupitz et al., 2004). The
X-ray crystal structure of IspH has been derived from E.
coli (PDB Id: 3KE8; Gräwert et al., 2010), A. aeolicus (PDB
Id: 3DNF; Rekittke et al., 2008) and P. falciparum (PDB Id:
4N7B; Rekittke et al., 2013). IspH consists of two domains,
a LytB domain for the binding of HMBDP and a Fe-S
cluster binding domain similar to IspG. Specific requirements
for the activity of IspG and IspH enzyme was proven by a
study in Saccharomyces cerevisiae, where the reconstruction of
the complete MEP pathway was aimed, however, even after
incorporation of all the necessary components including all the
enzymes, substrates and cofactors, the pathway remained non-
functional. It was concluded that a reducing environment and
compartmentalization is required for the functionality of these
enzymes (Partow et al., 2012).
Most of the inhibitors developed initially against IspG and
IspH targeted the Fe-S clusters, especially the unique fourth
iron site, but as most of the metallo-proteins in mammals,
including humans require these Fe-S clusters for their activity,
these inhibitors have selectivity issues. Substrate analogoues that
bind to IspG and IspH have been tried, but they could not turn
out to be potent inhibitors. Replacing the diphosphate group with
another moiety like carbamates or aminosulfonyl carbamates
showed only very weak inhibitory activity (Van Hoof et al., 2008).
In search of inhibitor, amongst various chemically synthesized
compounds, (E)-4-mercapto-3-methyl but-2 enyl diphosphate
(Alkyne diphosphate derivative) was shown to inhibit E. coli
IspH enzyme (Figure 5) where interaction was observed with
H41, S225, S226, N227, and S269 (Xiao et al., 2011; Span et al.,
2013). E126 residue is reported to be important for the activity
of IspH enzyme in E. coli and A. aeolicus, and a mutation at this
residue can cause a significant effect on its activity (Wang et al.,
2010). This residue is conserved in other organisms, including
Apicomplexans and plants.
Bhuyan et al. (2015) screened a large ligand data-set
containing diphospate group against the P. falciparum IspH
structure, and based on Goldscore and Chemscore identified
17 lead compounds amongst which 5-((hydroxymethyl)-O-
pyrophosphoryl) uracil shows best binding affinities with
Plasmodium IspH, and thus can be considered as its potential
inhibitor. Recently, the derivatives of diphosphonate such as
alkyl phosphate have been identified as potential inhibitors
for IspG and IspH enzymes of A. aeolicus, E. coli, and P.
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FIGURE 5 | X-ray crystal strucuture (PDB Id: 4H4E; Span et al., 2013) of E. coli IspH interacting with (E)-4-mercapto-3-methyl but-2 enyl diphosphate
(represented as stick). The inhibitory molecule interacts with H41, S225, S226, N227, and S269 residues of enzyme. CPK color scheme followed and distance
represented in Å.
falciparum (Guerra et al., 2014), however their exact mechanism
for inhibition is unknown.
MEP Pathway As a Potential Drug Target in
Plasmodium
MEP pathway and its enzymes present attractive new targets
for the development of broad-spectrum novel anti-microbial
and anti-malarial drugs. In the last decade, various researchers
have extensively explored these enzymes and their active sites to
identify/design probable inhibitors in prokaryotes (Hale et al.,
2012). In-silico studies and certain in-vitro assays performed on
the malaria parasite culture using drugs tested on prokaryotic
homologs have detailed few compounds that can block the
parasite growth by specifically binding to the enzymes of MEP
pathway. These compounds can be further analyzed for their
pharmacokinetics and pharmacological efficacy to establish them
as probable anti-malarials.
The natural antibiotic Fos, an inhibitor of IspC/DXR enzyme
has been widely used as an anti-bacterial and as an anti-malarial
to block in-vitro parasite cultures. Despite the apparent merits
of Fos, the drawbacks associated with it like low absorption
and shorter half-life, hampered its market introduction. Several
research groups attempted to improve its structural activity
by chemical modification, but none has been able to achieve
activity similar to Fos in vivo. However, the natural acetyl
derivative of Fos, FR900098, when tested for its anti-malarial
property has shown better activity (IC50 = 0.018 µM) than
Fos. Thus, an extensive research could help in the development
of new chemically synthesized derivatives of Fos and similar
compounds, to be used as potential anti-malarial.
With the studies performed on the initial enzymes of the
Plasmodium MEP pathway, showing the essentiality and the
uniqueness of the pathway for the survival of the parasite, it
becomes imperative to study the remaining enzymes of the
pathway. With the availability of the X-ray crystal structure of
almost half of them (IspC/DXR, IspF & IspH) from P. falciparum,
showing the conserved functional domains and substrate binding
sites, extrapolating the prokaryotic MEP inhibitors data to
Plasmodium is a promising way of identifying novel drugs.
Another approach can be to test the efficacy of clinically
approved and commercially established anti-bacterials targeting
these enzymes, as initially Fosmidomycin was also one amongst
those compounds.
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